Phase III data: Merck KGaA's Erbitux plus FOLFOX improves outcomes in RAS wild-type metastatic colorectal cancer

1 July 2016

New Phase III data confirms that adding Erbitux (cetuximab) to FOLFOX significantly improves outcomes in RAS wild-type metastatic colorectal cancer (mCRC).

Erbitux is already the standard-of-care treatment in many major markets, but German life sciences company Merck KGaA (MRK: DE) , which sees the drug as one of its strategic priority products, hopes this new data will ensure its patients have optimal access to this drug worldwide.

The findings were announced at the ESMO 18th World Congress on Gastrointestinal Cancer (WCGC) and come from the pivotal Phase III TAILOR study in patients from China, the first prospective trial to evaluate an anti-EGFR antibody in the first-line therapy of patients with RAS wild-type metastatic colorectal cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK